AMPH — Amphastar Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $2.34bn
- $2.71bn
- $644.40m
- 97
- 60
- 80
- 93
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 322 | 350 | 438 | 499 | 644 |
Cost of Revenue | |||||
Gross Profit | 132 | 143 | 200 | 249 | 354 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 322 | 339 | 354 | 397 | 450 |
Operating Profit | -0.039 | 11 | 83.5 | 102 | 194 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 60.2 | 4.64 | 84.1 | 116 | 171 |
Provision for Income Taxes | |||||
Net Income After Taxes | 46.5 | 1.1 | 63.5 | 92.6 | 140 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 48.9 | 1.4 | 62.1 | 91.4 | 138 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 48.9 | 1.4 | 62.1 | 91.4 | 138 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.054 | -0.141 | 1.04 | 1.83 | 2.68 |